Durata Therapeutics Prices Initial Public Offering

MORRISTOWN, N.J.--(BUSINESS WIRE)--Durata Therapeutics today announced the pricing of its initial public offering of 7,500,000 shares of common stock at a public offering price of $9.00 per share, before underwriting discounts. The shares are scheduled to begin trading on the NASDAQ Global Market on July 19, 2012 under the ticker symbol “DRTX."

In addition, the underwriters have an option for a period of 30 days to purchase up to an additional 1,125,000 shares of common stock from Durata at the public offering price, less the underwriting discount. The offering is expected to close on or about July 24, 2012.

BofA Merrill Lynch and Credit Suisse Securities (USA) LLC are acting as joint book-running managers for the offering. RBC Capital Markets, LLC and Wedbush PacGrow Life Sciences are acting as the co-managers for the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on July 18, 2012. The offering is being made only by means of a prospectus, copies of which may be obtained from BofA Merrill Lynch, 222 Broadway, 7th Floor, New York, NY 10038, Attn: Prospectus Department, or via email, at [e-mail] or Credit Suisse Securities (USA) LLC, Attn: Prospectus Department, One Madison Avenue, New York, NY 10010, telephone [phone], or via email, at [e-mail].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

About Durata Therapeutics

Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Durata is currently enrolling and dosing patients in two global Phase 3 clinical trials with its lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or abSSSI.